PRESS RELEASE published on 08/17/2023 at 13:00, 1 year 3 months ago CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
PRESS RELEASE published on 08/01/2023 at 13:00, 1 year 3 months ago CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
PRESS RELEASE published on 07/14/2023 at 13:00, 1 year 4 months ago CureVac Announces Update to the Management Team
PRESS RELEASE published on 07/13/2023 at 13:00, 1 year 4 months ago CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
PRESS RELEASE published on 06/20/2023 at 13:05, 1 year 5 months ago CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
PRESS RELEASE published on 06/20/2023 at 13:00, 1 year 5 months ago CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
PRESS RELEASE published on 06/19/2023 at 17:30, 1 year 5 months ago CureVac Announces Voting Results of General Meeting
PRESS RELEASE published on 05/30/2023 at 13:00, 1 year 5 months ago CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
PRESS RELEASE published on 05/19/2023 at 13:00, 1 year 6 months ago CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
PRESS RELEASE published on 05/08/2023 at 13:00, 1 year 6 months ago CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Published on 11/21/2024 at 22:05, 42 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 57 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 32 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 2 hours 37 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 2 hours 47 minutes ago Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:01, 3 hours 46 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 11 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 4 hours 49 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 4 hours 56 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 4 hours 56 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 15 hours 49 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 3 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
